At a Glance
- Companies: Nimbus Therapeutics, LLC; Eli Lilly and Company
- Location: Boston, Massachusetts, USA
- Deal value: Upfront/near‑term milestones totalling $55 million; up to ~$1.3 billion total including development, commercial and sales milestones, plus tiered royalties
- Focus area: Novel oral small‑molecule therapy for obesity and metabolic diseases
- Next steps: Apply Nimbus’ AI‑enhanced computational chemistry to advance early‑stage discovery program
What happened?
Nimbus Therapeutics has entered a multi‑year research collaboration and exclusive worldwide licence agreement with Eli Lilly and Company to discover a novel oral small‑molecule treatment for obesity and other metabolic diseases. This extends an existing partnership between the companies targeting AMPK in cardiometabolic indications, with Nimbus receiving $55 million in upfront and near‑term milestone payments and eligibility for up to approximately $1.3 billion in total milestones plus tiered royalties on global net sales.
Why does it matter?
The deal arrives amid surging demand for oral obesity therapies, as evidenced by Novo Nordisk’s recent launch of the Wegovy pill — the first oral GLP‑1 approved for weight loss, showing up to ~17% reduction if patients stay on treatment. Lilly, riding high on its tirzepatide franchise (Zepbound, Mounjaro), is diversifying beyond peptides into small‑molecule orals that could offer improved patient convenience, differentiated mechanisms and potential for broader cardiometabolic applications.
Who’s behind it?
Nimbus Therapeutics is a computational drug discovery company using AI‑enhanced structure‑based design to tackle challenging targets, with a pipeline spanning oncology (e.g. phase 1/2 WRN inhibitor NDI‑219216), immunology and metabolic diseases. Eli Lilly is a global leader in diabetes and obesity, aggressively expanding its metabolic portfolio through internal R&D and partnerships like this one.
How was it achieved?
The collaboration leverages Nimbus’ integrated platform—combining AI predictive models, computational chemistry, structure‑based design and experimental biology—to identify and optimise small molecules addressing an undisclosed obesity target. Lilly gains exclusive worldwide rights to resulting candidates, while Nimbus provides discovery support through nomination of leads for Lilly’s preclinical and clinical advancement.
What’s next?
The partners will focus on rapidly advancing the early‑stage programme toward preclinical candidates, with potential readouts informing expansion decisions. For Lilly, this bolsters its push for next‑generation oral obesity options to complement incretins like tirzepatide, while Nimbus gains validation and non‑dilutive funding to fuel its broader pipeline.
What are people saying? (optional)
Lilly’s Ruth Gimeno, Group VP of Diabetes and Metabolic R&D, praised Nimbus’ “exceptional ability to tackle complex drug discovery challenges” as key to developing innovative obesity therapies. Nimbus R&D President Peter Tummino highlighted how the company’s AI‑driven approach delivers “best‑in‑class potential” molecules, expressing excitement about combining this with Lilly’s metabolic expertise to impact patients with obesity.